Literature DB >> 27925329

Fragmented QRS Is a Novel Risk Factor for Ventricular Arrhythmic Events After Receiving Cardiac Resynchronization Therapy in Nonischemic Cardiomyopathy.

Miyako Igarashi1, Hiroshi Tada2, Hiro Yamasaki1, Kenji Kuroki1, Tomoko Ishizu1, Yoshihiro Seo1, Takeshi Machino1, Nobuyuki Murakoshi1, Yukio Sekiguchi1, Yuichi Noguchi3, Akihiko Nogami1, Kazutaka Aonuma1.   

Abstract

INTRODUCTION: A fragmented QRS (fQRS) is reported to be associated with a poor prognosis or sudden cardiac death (SCD) in patients with Brugada syndrome or ischemic heart disease. However, no studies have clarified the impact of the presence of an fQRS on SCD or ventricular arrhythmic events in patients receiving cardiac resynchronization therapy (CRT). This study aimed to clarify this point in patients with nonischemic cardiomyopathy. METHODS AND
RESULTS: This study included 137 heart failure patients with nonischemic cardiomyopathy who received CRT (NYHA functional class: II/III/IV = 25/84/28). The 12-lead ECGs before and after CRT were analyzed. The presence of an fQRS was decided in accordance with the definition in previous papers. Before the CRT, an fQRS was observed in 67 patients (fQRS-pre; 49%). However, it was masked in 35 (52% of fQRS-pre) patients after the CRT. Inversely, in 70 patients in whom an fQRS was absent before the CRT, it appeared after the CRT in 15 (21%) patients. As a result, 47 patients (34%) had an fQRS after the CRT (fQRS-post), and it was less than that before the CRT (P = 0.014). During 18 months of follow-up, SCD or ventricular arrhythmic events were observed more frequently in patients with an fQRS-post than in those without (36.2% vs. 3.3%, P < 0.001). A Cox regression analysis revealed that an fQRS-post was significantly associated with those events (hazard ratio = 9.18; 95% confidence interval = 2.45-34.48, P = 0.001).
CONCLUSION: In patients with nonischemic cardiomyopathy who received CRT, an fQRS-post was independently associated with SCD or ventricular arrhythmic events.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiac resynchronization therapy; fragmented QRS; heart failure; implantable cardioverter defibrillator; sudden cardiac death; ventricular arrhythmia

Mesh:

Year:  2017        PMID: 27925329     DOI: 10.1111/jce.13139

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  5 in total

1.  Baseline fragmented QRS is associated with increased all-cause mortality in heart failure with reduced ejection fraction: A systematic review and meta-analysis.

Authors:  Chanavuth Kanitsoraphan; Pattara Rattanawong; Poemlarp Mekraksakit; Pakawat Chongsathidkiet; Tanawan Riangwiwat; Napatt Kanjanahattakij; Wasawat Vutthikraivit; Saranapoom Klomjit; Subhanudh Thavaraputta
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-10-17       Impact factor: 1.468

2.  Analysis of the High-Frequency Content in Human QRS Complexes by the Continuous Wavelet Transform: An Automatized Analysis for the Prediction of Sudden Cardiac Death.

Authors:  Daniel García Iglesias; Nieves Roqueñi Gutiérrez; Francisco Javier De Cos; David Calvo
Journal:  Sensors (Basel)       Date:  2018-02-12       Impact factor: 3.576

Review 3.  Fragmented QRS is associated with ventricular arrhythmias in heart failure patients: A systematic review and meta-analysis.

Authors:  Nathan Engstrom; Geoffrey Dobson; Kevin Ng; Hayley Letson
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-11-11       Impact factor: 1.468

4.  QRS fragmentation is associated with increased risk of ventricular arrhythmias in high-risk patients; Data from the SMASH 1 Study.

Authors:  Nur Sourour; Egil Riveland; Terje Rømo; Patrycja Naesgaard; Harald Kjekshus; Alf Inge Larsen; Torbjørn Omland; Helge Røsjø; Peder Langeland Myhre
Journal:  Ann Noninvasive Electrocardiol       Date:  2022-07-15       Impact factor: 1.485

5.  Protective effects of N(2)‑L‑alanyl‑L‑glutamine mediated by the JAK2/STAT3 signaling pathway on myocardial ischemia reperfusion.

Authors:  Shan Liu; Yang Yang; Yan Qiu Song; Jie Geng; Qing Liang Chen
Journal:  Mol Med Rep       Date:  2018-02-02       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.